ISDA

Deposition Date 2015-06-15

Release Date 2015-07-29

Last Version Date 2023-09-27

Entry Detail

PDB ID:

5C25

Keywords:

TRANSFERASE, HYDROLASE/INHIBITOR

Title:

Crystal Structure of HIV-1 Reverse Transcriptase in Complex with 6-((4-((4-cyanophenyl)amino)-1,3,5-triazin-2-yl)amino)-5,7-dimethyl-2-naphthonitrile (JLJ639), a Non-nucleoside Inhibitor

Biological Source:

Source Organism:

Human immunodeficiency virus type 1 group M subtype B (isolate BH10) (Taxon ID: 11678)

Host Organism:

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.84 Å

R-Value Free:

0.26

R-Value Work:

0.21

R-Value Observed:

0.21

Space Group:

C 1 2 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:HIV-1 REVERSE TRANSCRIPTASE, P66 SUBUNIT
Gene (Uniprot):gag-pol
Mutations:C280S, K172A, K173A
Chain IDs:A
Chain Length:557
Number of Molecules:1
Biological Source:Human immunodeficiency virus type 1 group M subtype B (isolate BH10)

UniProt ID:P03366 Pfam ID:PF00078, PF06817, PF06815, PF00075 EC:3.1.26.13

Protein Blast

Polymer Type:polypeptide(L)
Molecule:HIV-1 REVERSE TRANSCRIPTASE, P51 SUBUNIT
Gene (Uniprot):gag-pol
Mutations:C280S
Chain IDs:B
Chain Length:428
Number of Molecules:1
Biological Source:Human immunodeficiency virus type 1 group M subtype B (isolate BH10)

UniProt ID:P03366 Pfam ID:PF00078, PF06817, PF06815, PF00075 EC:3.1.26.13

Ligand Molecules

639

SO4

Primary Citation

Discovery and crystallography of bicyclic arylaminoazines as potent inhibitors of HIV-1 reverse transcriptase.

Lee, W.G, Frey, K.M, Gallardo-Macias, R, Spasov, K.A, Chan, A.H, Anderson, K.S, Jorgensen, W.L.Show

Bioorg.Med.Chem.Lett. 25 4824 4827 (2015)

PMID: 26166629 DOI: 10.1016/j.bmcl.2015.06.074

Abstact

Non-nucleoside inhibitors of HIV-1 reverse transcriptase (HIV-RT) are reported that incorporate a 7-indolizinylamino or 2-naphthylamino substituent on a pyrimidine or 1,3,5-triazine core. The most potent compounds show below 10 nanomolar activity towards wild-type HIV-1 and variants bearing Tyr181Cys and Lys103Asn/Tyr181Cys resistance mutations. The compounds also feature good aqueous solubility. Crystal structures for two complexes enhance the analysis of the structure-activity data.

Legend

Protein

Chemical

Disease

Primary Citation of related structures